Kornimate/medical-research-clean huggingface dataset:
developing text-based support for parents of adolescents after an emergency department visit

Conditions: Suicide

Summary: the researchers seek to develop a text message intervention for caregivers of adolescents at elevated suicide risk following discharge from emergency department (ed) care.

participants in the trial included 120 youth-parent dyads (120 youths and 120 parents). as the ultimate focus of the intervention is on improving youth outcomes, participant-related descriptives are provided for youth participants, except where noted specifically to be parent-related data.

Eligibility criteria:
parent eligibility: inclusion criteria: * parent of eligible teen exclusion criteria: * not owning a cell phone with text messaging capability. teen eligibility: inclusion criteria: * recent suicidal ideation (within last 2 weeks) and/or suicide attempt within the last month. exclusion criteria: * youth with severe cognitive impairment or altered mental status (e.g., psychosis, manic state) * youth with severe aggression/agitation * no availability of a legal guardian

Keywords: emergency department
can pregabalin reduce the frequency and severity of dry eye symptoms after laser-assisted in situ keratomileusis?

Conditions: Dry Eye

Summary: can lyrica (pregabalin) help prevent severe dry eye post lasik surgery?

dry eye symptoms can occur after lasik surgery. they generally get better with time but in some patients, they can persist. the investigators believe that in some individuals, dry eye symptoms after lasik persist because the nerves in the cornea become hypersensitive. the investigators wish to study if a medication, called pregabalin, can protect corneal nerves at the time of lasik surgery and decrease the frequency and severity of dry eye symptoms 6 months after surgery. this medication has been used in a similar way to reduce the frequency of uncomfortable sensations after other surgeries (knee, abdomen) but has never been studied in lasik surgery.

Eligibility criteria:
inclusion criteria: * 18 and 65 years of age * undergoing lasik (unilateral or bilateral procedure). * females of child-bearing age will need a negative urine or serum pregnancy test at the screening visit. * ocular and systemic medication regimen has been stable for 3 months exclusion criteria: * pregnant or lactating, participating in another study with an investigational drug within one month prior to screening * using gabapentin, pregabalin, anti-convulsants, duloxetine, venlafaxine (snri), or tri-cyclic antidepressants * have a history of allergic, anaphylactic reaction, or severe systemic response to pregabalin or gabapentin * use corticosteroids chronically or during the month prior to surgery, or have a history of corneal disease (hsv or varicella zoster keratitis, prior corneal incisions (cataract surgery, radial keratotomy, lasik), prior corneal ulcer). * patients with systemic co-morbidities that may confound de such as hiv, sarcoidosis, graft-versus host disease or a collagen vascular disease. * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * prisoners

Keywords: laser-assisted in situ keratomileusis dry eye symptoms lasik prevention
family mobilephone otoscopy in diagnostics of otitis media

Conditions: Otitis Media

Summary: this is a one-center clinical study carried out in turku, finland. the study patients will be randomly allocated to one of the two parallel study groups (teaching group and control group). the hypothesis is that the diagnostic quality of tympanic membrane imagines is better when parents have been taught to conduct middle ear examination with a cellphone otoscope (cellscopeoto) as compared to no teaching. furthermore, this study aims at evaluating the diagnostic feasibility of cellphone otoscopy.


Eligibility criteria:
inclusion criteria: * age 6 - 35 mo * parents have iphone 5, 5s or 6 * child is in daycare * child has had at least one acute otitis media within 90 days preceding the enrollment * family agrees to give a mortgage of 40 euros from the cellscopeoto exclusion criteria: * tympastonomy tube present in tympanic membrane * chronic perforation of the tympanic membrane * condition of head/neck anomaly to affect middle ear or ear canal anatomy * one child from the family already participating

Keywords: otoscopy otitis media cellphone family
a study to investigate the safety and efficacy of pa21 (velphoro®) and calcium acetate (phoslyra®) in paediatric and adolescent chronic kidney disease (ckd) patients with hyperphosphataemia

Conditions: Hyperphosphatemia

Summary: this is a phase 3, open-label, randomised, active-controlled, parallel group, multicentre study to investigate the safety and efficacy of pa21 (velphoro®) and calcium acetate (phoslyra®) in paediatric and adolescent ckd patients with hyperphosphataemia. the aim of this phase 3 clinical study is to demonstrate similar efficacy of pa21 (velphoro) in paediatric and adolescent patients with ckd, and to provide safety and dosing information for this patient population. the phoslyra (comparator) group provides information for a descriptive comparison of pa21 against a commonly used calcium-based phosphate binder (calcium acetate).


Eligibility criteria:
inclusion criteria: 1. subjects 0 to \<18 years at time of consent. 2. subjects with hyperphosphataemia 3. subjects ≥1 year with ckd stages 4-5 defined by a glomerular filtration rate \<30 ml/min/1.73 m2 or with ckd stage 5d receiving adequate maintenance haemodialysis (hd) or peritoneal dialysis (pd) for at least 2 months prior to screening. 4. subjects \<1 year must have ckd. 5. appropriate written informed consent and, where appropriate/required assent, have been provided. exclusion criteria: 1. subjects with hypercalcaemia at screening 2. subjects with intact parathyroid hormone (ipth) levels \>700 pg/ml at screening. 3. subjects who are pb naïve who weigh \<5 kg at screening. subjects receiving stable doses of pbs who weigh \<6 kg at screening 4. subjects requiring feeding tube sizes ≤6 fr (french catheter scale). 5. subjects with history of major gastrointestinal surgery or significant gastrointestinal disorders. 6. subjects with hypocalcaemia (serum total corrected calcium \<1.9 mmol/l; \<7.6 mg/dl) at screening. 7. subject is pregnant (e.g., positive human chorionic gonadotropin test) or breast feeding. 8. subject has a significant medical condition(s)

Keywords: pa21 phosphate binder
acute kidney injury in patients with covid-19

Conditions: Covid19; Acute Kidney Injury

Summary: we aimed to investigate the effect of acute kidney injury (aki̇) on the prognosis of patients hospitalised for covid-19.

the effect of acute kidney injury (aki̇) on the prognosis of patients hospitalised for covid-19. patients hospitalised for covid-19 and acute kidney injury will be enrolled. the duration of hospitalisation, mortality rates will be compared in covid-19 patients with and without acute kidney injury.

Eligibility criteria:
inclusion criteria: * patients hospitalised with covid-19. * patients hospitalised with covid-19 with acute kidney injury exclusion criteria: -
serotonin and the upper airway in obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the purpose of this study is to determine if a certain medication, alone or combined with another medication, will increase muscle activity in the upper airway in people who do and people who do not have sleep apnea. the medications being studied are paroxetine, a commonly used antidepressant, and 5 hydroxy-tryptophan (5htp), which also can be used as a dietary supplement without a prescription. because the effects of paroxetine in previous studies were not very large, we will also study it combined with 5htp to see if the effect on the upper airway muscles is greater.


Eligibility criteria:
group a: 20 adult patients with mild to severe sleep apnea. if patients are being treated with nasal cpap, they will continue treatment except on study nights. group b: 20 normal adult non-snoring subjects.

Keywords: serotonin sleep apnea syndrome pharyngeal muscles
group alcohol interventions for college men

Conditions: Alcohol Drinking; Sexual Behavior

Summary: the objective of the proposed project is to conduct a randomized controlled trial (rct) comparing sexual assault perpetration and related outcomes (i.e., bystander behavior; rape myth acceptance) for men who receive a group alcohol intervention only to men who receive a group integrated alcohol and sexual assault intervention.

although research suggests that sexual assault interventions based on bystander and social norms theory help to reduce sexual assault among college men, these programs do not completely eliminate sexual assault and their effects tend to fade over time. unfortunately, there is minimal research on whether (1) decreasing alcohol use concurrently decreases sexual assault perpetration among college men and (2) whether alcohol interventions can be incorporated into existing sexual assault programs for college men (i.e., bystander/social norms programs). therefore, the objective of the proposed project is to conduct a randomized controlled trial (rct) comparing sexual assault perpetration and related outcomes (i.e., bystander behavior; rape myth acceptance) for men who receive a group alcohol intervention only to men who receive a group integrated alcohol and sexual assault intervention. specifically, the alcohol only intervention will consist of the brief alcohol screening and intervention for college students (basics), an empirically-supported intervention for college student drinking. the integrated alcohol and sexual assault intervention, which we have termed ohio university's combined alcohol and normative intervention program (ou can), will be modeled after basics and empirically-supported bystander and social norms interventions for sexual assault. the current study will recruit 100 college men who are sanctioned by their university to receive an alcohol intervention for violating a campus alcohol policy: by definition an indicated and at-risk population for sexual assault perpetration. men will be followed for 6 months to determine the effects of the intervention on sexual assault perpetration and other primary outcomes (e.g., bystander behavior).

Eligibility criteria:
inclusion criteria: * must be 18 or older; must be an ohio university student; must be male; must be sanctioned to receive an alcohol intervention by ohio university exclusion criteria: * under the age of 18
monitoring of encephalopathy in cirrhotic patients admitted in intensive care

Conditions: Hepatic Encephalopathy; Liver Cirrhosis

Summary: this study seeks to assess the impact of the standardization of nursing supervision of patients with hepatic encephalopathy using a grid of appropriate surveillance for the prevention of complications in the icu.

as part of improving the quality of care, the paramedic team has developed an evaluation grid quantitative parameters of the early warning score, the glasgow coma score modified and signs suggestive of hepatic encephalopathy.a course of action was later formalized as a function of score when using the grid monitoring. the aim of the study is to demonstrate that the standardization of monitoring by a quantitative evaluation grid reduces the complications of hepatic encephalopathy. for this, investigator's team will study a before / after standardization by comparing two groups of patients, icu liver - digestive beaujon hospital, and suffering from hepatic encephalopathy associated with liver cirrhosis and therapeutic care project formalized. for the first group have been no specific nursing practice, investigator's team will take a retrospective study. for the second group have been monitoring a standard, investigator's team will take a prospective study. the total number of patients in each group will be 121 a total of 242. the frequency of pneumonia is the primary outcome. secondary endpoints were the occurrence of ventilatory disorders, the presence of shock and premature death of the patient during his hospitalization. investigator's team will compare the frequency of occurrence of these complications in both groups. data will be collected using a questionnaire based on information from the software and gildae dxcare. the prospective study will last 26 months. for the retrospective study, the msi will publish a list of all patients meeting the inclusion criteria and icu liver - digestive in the 26 months preceding the start of the study. the interest of this work is to formalize an objective tool for assessing hepatic encephalopathy and improve communication among caregivers.

Eligibility criteria:
inclusion criteria : * hepatic encephalopathy * liver cirrhosis * treatment plan
neural correlates of stress hormones

Conditions: Borderline Personality Disorder; PTSD

Summary: to investigate which neuronal correlates underlie cortisol-induced enhancement of memory retrieval in ptsd and bpd.

the investigators have recently shown that hydrocortisone enhances rather than impairs memory retrieval in patients with posttraumatic stress disorder (ptsd) and borderline personality disorder (bpd). in contrast, in healthy participants memory retrieval was impaired after hydrocortisone compared to placebo. the proposed studies aim to further investigate these findings and to understand the underlying neuronal correlates. thus, the mechanisms of enhanced memory retrieval after hydrocortisone in patients with bpd and ptsd will be investigated by fmri. in a placebo-controlled study, the effects of 10mg hydrocortisone on brain activity, in particular the hippocampus, will be investigated in patients with ptsd and bpd and will be compared with those in healthy control participants. during the fmri session, a declarative memory task (retrieval of a previous learned word list) and an autobiographical memory test will be performed. effects of hydrocortisone on resting state brain activity and the neuronal correlates of memory retrieval will be analysed.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of borderline personality disorder * clinical diagnosis of ptsd * females without psychiatric disorders as control group * right handed exclusion criteria: * fmri exclusion criteria e.g. metal implants, pregnancy, left-handedness, and claustrophobia.
assessment of myocardial viability using multidetector computed tomography

Conditions: Myocardial Infarction

Summary: to perform a comprehensive evaluation of multidetector ct myocardial enhancement patterns in patients with an acute st elevation mi. in particular we plan to assess the relationship between regions with early hypoperfusion and/or late hyperenhancement, and myocardial viability.

20 patients admitted to iccu with st elevation mi, and treated with primary angioplasty on admission, will undergo between day 2 and 7 post-mi the following exams: a) multidetector ct: regular scan plus late scan at 10 minutes, to evaluate coronary arteries, regional function and myocardial enhancement, b) echocardiography with echo-contrast to evaluate function and size of abnormally contracting region and remodeling, c) nuclear studies: rest early and late thallium spect, to evaluate perfusion and viability. at 3 months a second echo will be performed to assess recovery of abnormal segments. the perfusion defects on msct will be compared with the other modalities and at 3 months will be used to evaluate recovery of myocardial function i.e. viability. parameters that will be evaluated include opacity of hypoenhanced segments, ratio of normal to abnormal segments, change in opacity between early and late scans, size and transmurality of hypoenhanced segments, and their relation to regional contraction.

Eligibility criteria:
inclusion criteria: * acute st elevation myocardial infarction * after primary angioplasty exclusion criteria: * iodine allergy * renal failure * old mi * arrhythmia * inability to perform 20 second breath-hold

Keywords: mdct viability
evaluation of the efficacy and safety of azeliragon (ttp488) in patients with mild alzheimer's disease

Conditions: Alzheimer's Disease

Summary: this is a study to evaluate the efficacy and safety of azeliragon in patients with mild alzheimer's disease. patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.


Eligibility criteria:
inclusion criteria: * diagnosis of probable alzheimer disease (ad) with documented evidence of progression of disease * mini mental state examination (mmse) score of 21-26, inclusive * clinical dementia rating global score of 0.5 or 1 * rosen-modified hachinski ischemia score less than or equal to 4 * brain magnetic resonance imaging (mri) consistent with the diagnosis of probable ad * concurrent use of cholinesterase inhibitor or memantine with stable dose for at least 3 months prior to randomization * caregiver willing to participate and be able to attend clinic visits with patient * ability to ingest oral medications exclusion criteria: * significant neurological or psychiatric disease other than alzheimer's disease * participants with evidence or history of severe drug allergies (resulting in dyspnea or severe rash). * any contraindications to mri (e.g., clinically significant claustrophobia, non-removable ferromagnetic implants). patients with contraindications to mri may undergo computed tomography (ct) on approval by sponsor. * any contraindications to the fdg-pet study (e.g. allergy to any component of the fdg dose) in the cohort undergoing a pet scan. * previous exposure to investigational or non-investigational therapies for alzheimer's disease within 6 months of screening * history of cancer within the last 5 years except adequately treated cervical carcinoma in-situ, cutaneous basal cell or squamous cell cancer, or non-progressive prostate cancer not requiring treatment * women of childbearing potential * uncontrolled blood pressure and/or blood pressure above 160/100 * prescription medical food intended for dietary management of the metabolic processes associated with alzheimer's disease. * diagnosis or history of cerebrovascular stroke, severe carotid stenosis, cerebral hemorrhage, intracranial tumor, subarachnoid hemorrhage. * patients with unstable, uncontrolled diabetes (hba1c \> 7.7%) and those requiring insulin.

Keywords: alzheimer's disease rage adas-cog cdr-sb
encouraging healthy food shopping and eating behaviors by price reduction: a community supermarket study

Conditions: Obesity

Summary: the investigators plan to test the effect of price reduction of fruits and vegetables and non-caloric beverages on food purchasing, food intake, body weight, and body composition of primarily single adult shoppers. one hundred subjects will be randomized to an experimental or control group for a 4 month period. in the experimental group, there will be an automated 50% reduction in fruits vegetables and non-caloric beverages during the middle 2-month period. the investigators expect to observe significant changes in food shopping and eating behavior during this period, which should lead to body weight and fat loss. some of these new shopping patterns should persist in the last month of the study even though prices revert.


Eligibility criteria:
inclusion criteria: * regularly buy 50% of groceries at designated supermarket * primary food shopper for household, shopping for up to one other person, not counting children ≤ 6 years old exclusion criteria: * significant medical or psychiatric conditions * participation in a weight loss program or a related study
cardiovascular risk profile in patients with congenital adrenal hyperplasia

Conditions: Congenital Adrenal Hyperplasia

Summary: treatment with glucocorticoids and mineralocorticoids has changed congenital adrenal hyperplasia (cah) from a fatal to a chronic lifelong disease. long-term treatment, in particular the chronic (over-)treatment with glucocorticoids, may have an adverse effect on the cardiovascular risk profile in adult cah patients. the objective of this study was to evaluate the cardiovascular risk profile of adult cah patients.

treatment with glucocorticoids and mineralocorticoids has changed congenital adrenal hyperplasia (cah) from a fatal to a chronic lifelong disease. long-term treatment, in particular the chronic (over-)treatment with glucocorticoids, may have an adverse effect on the cardiovascular risk profile in adult cah patients. the objective of this study was to evaluate the cardiovascular risk profile of adult cah patients. design: case control study primary objective : detection of cardiovascular damage in patients with classical or non classical cah diagnosed in childhood. the patients will be compared with age- and gender- and tobacco status- matched control. secondary objective study of microvascular function evaluation of cardiovascular risk factors total cumulative (tcg) and total average (tag) glucocorticoid doses will be calculated from pediatric and adult files and correlated to arterial macro- and microcirculatory dysfunction. primary outcome ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs and left ventricular function secondary outcome peripheral and central blood pressure skin capillary density and pulse-wave velocity glucose and insulin during an oral glucose tolerance test circulating cardiovascular risk markers (hscrp, adiponectin, interleukin-6) lipid profile anthropometry, fat and lean mass measured by dual-energy x-ray absorptiometry total cumulative dose of glucocorticoid number of subjects : 90 patients/90 controls inclusion criteria of cah patients * patients \> 18 yrs with classical or non classical cah diagnosed during childhood * absence of known cardiovascular disease * absence of combined oral contraceptives during the previous month inclusion criteria of controls * age under 18 * absence of known cardiovascular disease * absence of combined oral contraceptives during the previous month duration of the inclusion period: 3 years

Eligibility criteria:
inclusion criteria : patients * patients \> 18 yrs with classical or non classical cah diagnosed during childhood * absence of known cardiovascular disease * absence of combined oral contraceptives during the previous month inclusion criteria : controls * age \> 18 yrs * absence of known cardiovascular disease * absence of combined oral contraceptives during the previous month exclusion criteria : * blood donation during the previous 3 months * cardiovascular disease * treatment by combined oral contraceptives * pregnancy

Keywords: congenital adrenal hyperplasia (cah) cardiovascular risk microvascular dysfunction